{"id":1758015,"date":"2026-06-26T17:27:53","date_gmt":"2026-06-26T11:57:53","guid":{"rendered":"https:\/\/pharmint.net\/product\/buy-epcoritamab-tepkinly-epkinly-in-india\/"},"modified":"2026-06-26T17:35:45","modified_gmt":"2026-06-26T12:05:45","slug":"epcoritamab-tepkinly-epkinly-in-india","status":"publish","type":"product","link":"https:\/\/pharmint.net\/es\/product\/epcoritamab-tepkinly-epkinly-in-india\/","title":{"rendered":"Epcoritamab (Tepkinly \/ Epkinly)"},"content":{"rendered":"

Tepkinly \/ Epkinly (Epcoritamab)<\/strong> is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and in relapsed or refractory follicular lymphoma (FL).<\/span><\/p>\n

<\/p>\n

Dosage: <\/span><\/p>\n

DLBCL and High-grade B-cell Lymphoma<\/span><\/p>\n\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n
Cyclea<\/span><\/span><\/td>\nDay of treatment<\/span><\/td>\nDose of Tepkinly \/ Epkinly<\/span><\/td>\n<\/tr>\n
\n
Cycle 1<\/div>\n<\/td>\n
1<\/td>\nStep-up dose 1<\/td>\n0.16 mg<\/td>\n<\/tr>\n
8<\/td>\nStep-up dose 2<\/td>\n0.8 mg<\/td>\n<\/tr>\n
15<\/td>\nFirst full dose<\/td>\n48 mg<\/td>\n<\/tr>\n
22<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 2 and 3<\/td>\n1, 8, 15 and 22<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 4 to 9<\/td>\n1 and 15<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycle 10 and beyond<\/td>\n1 and 15<\/td>\n48 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

a<\/span>Cycle = 28 days<\/p>\n

Tepkinly \/ Epkinly as Monotherapy for FL<\/span><\/p>\n\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n
Cyclea<\/span><\/span><\/td>\nDay<\/span><\/td>\nDose of Tepkinly \/ Epkinly<\/span><\/td>\n<\/tr>\n
\n
Cycle 1<\/div>\n<\/td>\n
1<\/td>\nStep-up dose 1<\/td>\n0.16 mg<\/td>\n<\/tr>\n
8<\/td>\nStep-up dose 2<\/td>\n0.8 mg<\/td>\n<\/tr>\n
15<\/td>\nStep-up dose 3<\/td>\n3 mg<\/td>\n<\/tr>\n
22<\/td>\nFirst full dose<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 2 and 3<\/td>\n1, 8, 15 and 22<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 4 to 9<\/td>\n1 and 15<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycle 10 and beyond<\/td>\n1 and 15<\/td>\n48 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

a<\/span>Cycle = 28 days<\/p>\n

Tepkinly \/ Epkinly in combination with Lenalidomide and Rituximab for FL<\/span><\/p>\n\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n
Cyclea<\/span><\/span><\/td>\nDay<\/span><\/td>\nDose of Tepkinly \/ Epkinly<\/span><\/td>\n<\/tr>\n
\n
Cycle 1<\/div>\n<\/td>\n
1<\/td>\nStep-up dose 1<\/td>\n0.16 mg<\/td>\n<\/tr>\n
8<\/td>\nStep-up dose 2<\/td>\n0.8 mg<\/td>\n<\/tr>\n
15<\/td>\nStep-up dose 3<\/td>\n3 mg<\/td>\n<\/tr>\n
22<\/td>\nFirst full dose<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 2 and 3<\/td>\n1, 8, 15 and 22<\/td>\n48 mg<\/td>\n<\/tr>\n
Cycles 4 to 12<\/td>\n1<\/td>\n48 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

a<\/span>Cycle = 28 days<\/p>\n

Adverse effects:<\/span><\/p>\n